Mechanism & Mode of action

The mechanism of action (MOA) of a drug means identifying which proteins it binds to, and the mode of action (MoA) means knowing which pathways the drug affects.

Understanding the mechanism of action of a drug entails identifying which proteins it binds to, while understanding the mode of action means knowing which pathways the drug affects and, consequently, its impact (e.g., a drug with an anti-inflammatory function).

From phenotype to pathway

Exploring the mechanism and/or mode of action of a drug usually involves first noticing a phenotype or phenomenon, and then exploring which pathways are responsible for such observation. A key step on deciphering the mode of action, is understanding the sequence of effects, to be able to pinpoint all the potential pathways affected, and potential outcomes. Common ways for analyzing this, are by performing transcriptomic and proteomic analysis, amongst other types of omics studies.

If you are looking for the ideal in vivo preclinical model to understand the MOA and MoA of your construct, genOway can help you with the next steps. 

4 steps you need to follow for successful MoA analysis of your compound

I -

Define your target and scientific questions​

II -

Find the right model for your research​

III -

Design your experiments – Scientific Advice & Support​

IV -

Perform your first experiments at genOway or at a trusted CRO

Related resources and publications

Other applications

Efficacy

Efficacy testing is a critical step in drug development, assessing whether a drug candidate achieves its intended effect at various doses.​

Learn more

Safety

Safety testing is a critical step in drug development, assessing whether a drug candidate is non toxic.​

Learn more

Pharmacokinetic & Biodistribution

Pharmacokinetic (PK) analysis is a critical step in drug development, assessing how the body impacts the drug, following administration.

Learn more
Scientific excellence

From model design to experimental results
Featured in 600+ scientific articles

Collaborative approach

Collaboration with 17 Top Pharmas,
170+ Biotechs and 380+ Academic Institutions

Robust validation data on catalog models

Generated with biopharma partners and in-house

Innovative technologies

and guaranteed freedom to operate

Easy access to models

Models with certified health status from professional breeders in US and Europe